Literature DB >> 27066190

The Institute for Clinical and Economic Review and Its Growing Influence on the US Healthcare.

Laura T Pizzi1.   

Abstract

Year:  2016        PMID： 27066190      PMCID： PMC4822973     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  7 in total

Review 1.  Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Authors:  S Vincent Rajkumar; Jean Luc Harousseau
Journal:  Blood       Date:  2016-10-14       Impact factor: 22.113

2.  Taking stock of cost-effectiveness analysis of healthcare in China.

Authors:  Thomas Butt; Gordon G Liu; David D Kim; Peter J Neumann
Journal:  BMJ Glob Health       Date:  2019-05-14

3.  The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab.

Authors:  Diana Brixner; Gary Oderda; Joseph Biskupiak; Douglas S Burgoyne; Steven G Avey; Steven R Feldman
Journal:  Am Health Drug Benefits       Date:  2019-02

4.  IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.

Authors:  Barnaby Hunt; Michelle Mocarski; William J Valentine; Jakob Langer
Journal:  Diabetes Ther       Date:  2017-03-27       Impact factor: 2.945

5.  Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research.

Authors:  Thomas Patton; Paul Revill; Mark Sculpher; Annick Borquez
Journal:  Subst Use Misuse       Date:  2022-02-14       Impact factor: 2.164

6.  Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile.

Authors:  Ting Wang; Neil McAuslane; Wim G Goettsch; Hubert G M Leufkens; Marie L De Bruin
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

7.  Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective.

Authors:  Diane Whalley; Gary Globe; Rebecca Crawford; Lynda Doward; Eskinder Tafesse; John Brazier; David Price
Journal:  Health Qual Life Outcomes       Date:  2018-08-03       Impact factor: 3.186
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.